## WHAT IS CLAIMED IS:

- 1. A stable isotonic reconstituted formulation comprising a protein in an amount of at least about 50 mg/mL and a diluent, which reconstituted formulation has been prepared from a lyophilized mixture of a protein and a lyoprotectant, wherein the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
- 2. The formulation of claim 1 wherein the lyoprotectant is sucrose.
- 3. The formulation of claim \wherein the lyoprotectant is trehalose.
- 4. The formulation of claim 1 which further comprises a buffer.
- 5. The formulation of claim 4 wherein the buffer is histidine or succinate.
- 6. The formulation of claim 1 which further comprises a surfactant.
- 7. The formulation of claim 1 which is sterile
- 8. A stable reconstituted formulation comprising an antibody in an amount of at least about 50 mg/mL and a diluent, which reconstituted formulation has been prepared from a lyophilized mixture of an antibody and a lyoprotectant, wherein the antibody concentration in the reconstituted formulation is about 2-40 times greater than the antibody concentration in the mixture before lyophilization.
- 9. The formulation of claim 8 wherein the antibody is an anti-\gE antibody.
- 10. The formulation of claim 8 wherein the antibody is an anti-HER2 antibody.
- 11. The formulation of claim 8 wherein the antibody is a full length humanized antibody.

- 12. The formulation of claim 8 which is isotonic.
- 13. A method for preparing a stable isotonic reconstituted formulation comprising reconstituting a lyophilized mixture of a protein and a lyoprotectant in a diluent such that the protein concentration in the reconstituted formulation is at least 50 mg/mL, wherein the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
- 14. The method of claim 13 wherein the lyoprotectant is sucrose.
- 15. The method of claim 13 wherein the lyoprotectant is trehalose.
- 16. The method of claim 13 wherein the yophilized mixture further comprises a bulking agent.
- 17. The method of claim 13 wherein the protein is an antibody.
- 18. A method for preparing a formulation comprising the steps of:
  - (a) lyophilizing a mixture of a protein and a lyoprotectant; and
- (b) reconstituting the lyophilized mixture of step (a) in a diluent such that the reconstituted formulation is isotonic and stable and has a protein concentration of at least about 50 mg/mL.
- 19. The method of claim 18 wherein the protein concentration in the reconstituted formulation is from about 80 mg/mL to about 300 mg/mL.
- 20. The method of claim 18 wherein the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
- 21. The method of claim 18 wherein lyophilization is performed at a shelf temperature maintained at about 15-30°C throughout the entire lyophilization process.
- 22. An article of manufacture comprising:

7

- (a) a container which holds a lyophilized mixture of a protein and a lyoprotectant; and
- (b) instructions for reconstituting the lyophilized mixture with a diluent to a protein concentration in the reconstituted formulation of at least about 50 mg/mL.
- 23. The article of manufacture of claim 22 wherein the protein concentration in the reconstituted formulation is about 2-40 times greater than the protein concentration in the mixture before lyophilization.
- 24. The article of manufacture of claim 22 further comprising a second container which holds a diluent.
- 25. The article of manufacture of claim 24 wherein the diluent is bacteriostatic water for injection (BWFI) comprising an aromatic alcohol.
- 26. A formulation comprising a lyophilized mixture of a lyoprotectant and an antibody, wherein the molar ratio of lyoprotectant:antibody is about 100-1500 mole lyoprotectant:1 mole antibody.
- 27. A method for treating a mammal comprising administering a therapeutically effective amount of the formulation of claim 1 to the mammal, wherein the mammal has a disorder requiring treatment with the protein in the formulation.
- 28. The method of claim 27 wherein the formulation is administered subcutaneously.
- 29. A formulation comprising anti-HER2 antibody in amount from about 5-40 mg/mL, sucrose or trehalose in an amount from about 10-100 mM, a buffer and a surfactant.
- 30. The formulation of claim 29 further comprising a bulking agent.
- 31. The formulation of claim 30 wherein the bulking agent is manual or glycine.
- 32. The formulation of claim 29 which is lyophilized and stable at 30° & for at least 6 months.

- 33. The formulation of claim 32 which is reconstituted with a diluent such that the anti-HER2 antibody concentration in the reconstituted formulation is from about 10-30 mg/mL, wherein the reconstituted formulation is stable at 2-8°C for at least about 30 days.
- 34. The formulation of claim 33 wherein the diluent is bacteriostatic water for injection (BWFI) comprising an aromatic alcohol.
- 35. A formulation comprising anti-IgE anabody in amount from about 5-40 mg/mL, sucrose or trehalose in an amount from about 80,300 mM, a buffer and a surfactant.
- 36. The formulation of claim 35 which is lyophilized and stable at about 30°C for at least 1 year.